172 related articles for article (PubMed ID: 16019573)
21. Long term gene therapy of Parkinson's disease using immortalized rat glial cell line with tyrosine hydroxylase gene.
Zhuo M; Xu DH; Cao L; Xu LF; Yu FR; Zheng ZC; Liu XY
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Dec; 35(12):1066-71. PubMed ID: 14673496
[TBL] [Abstract][Full Text] [Related]
22. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
[TBL] [Abstract][Full Text] [Related]
23. Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after coculture with cellular substrates and exposure to GDNF.
Buytaert-Hoefen KA; Alvarez E; Freed CR
Stem Cells; 2004; 22(5):669-74. PubMed ID: 15342931
[TBL] [Abstract][Full Text] [Related]
24. Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.
Jollivet C; Aubert-Pouessel A; Clavreul A; Venier-Julienne MC; Montero-Menei CN; Benoit JP; Menei P
Neurosci Lett; 2004 Feb; 356(3):207-10. PubMed ID: 15036631
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
Ericson C; Georgievska B; Lundberg C
Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro.
Borgal L; Hong M; Sadi D; Mendez I
Neuroscience; 2007 Jul; 147(3):712-9. PubMed ID: 17583436
[TBL] [Abstract][Full Text] [Related]
27. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
Brizard M; Carcenac C; Bemelmans AP; Feuerstein C; Mallet J; Savasta M
Neurobiol Dis; 2006 Jan; 21(1):90-101. PubMed ID: 16084732
[TBL] [Abstract][Full Text] [Related]
28. Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats.
Date I; Shingo T; Yoshida H; Fujiwara K; Kobayashi K; Takeuchi A; Ohmoto T
Cell Transplant; 2001; 10(4-5):397-401. PubMed ID: 11549061
[TBL] [Abstract][Full Text] [Related]
29. Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector.
Chtarto A; Yang X; Bockstael O; Melas C; Blum D; Lehtonen E; Abeloos L; Jaspar JM; Levivier M; Brotchi J; Velu T; Tenenbaum L
Exp Neurol; 2007 Mar; 204(1):387-99. PubMed ID: 17223106
[TBL] [Abstract][Full Text] [Related]
30. Glial cell line-derived neurotrophic factor (GDNF) is required for differentiation of pontine noradrenergic neurons and patterning of central respiratory output.
Huang L; Guo H; Hellard DT; Katz DM
Neuroscience; 2005; 130(1):95-105. PubMed ID: 15561428
[TBL] [Abstract][Full Text] [Related]
31. Co-grafts of fetal ventral mesencephalon and fibroblasts expressing sonic hedgehog: effect on survival and function of dopamine grafts.
Yurek DM; Fletcher-Turner A; Moore J; Chai L; Mahanthappa N
Cell Transplant; 2001; 10(8):665-71. PubMed ID: 11814108
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease.
Lu L; Zhao C; Liu Y; Sun X; Duan C; Ji M; Zhao H; Xu Q; Yang H
Brain Res Brain Res Protoc; 2005 May; 15(1):46-51. PubMed ID: 15878150
[TBL] [Abstract][Full Text] [Related]
33. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD
Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273
[TBL] [Abstract][Full Text] [Related]
34. Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.
Duan D; Yang H; Zhang J; Zhang J; Xu Q
Exp Brain Res; 2005 Mar; 161(3):316-24. PubMed ID: 15480595
[TBL] [Abstract][Full Text] [Related]
35. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.
Do Thi NA; Saillour P; Ferrero L; Dedieu JF; Mallet J; Paunio T
Gene Ther; 2004 May; 11(9):746-56. PubMed ID: 14724667
[TBL] [Abstract][Full Text] [Related]
36. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects.
Ai Y; Markesbery W; Zhang Z; Grondin R; Elseberry D; Gerhardt GA; Gash DM
J Comp Neurol; 2003 Jun; 461(2):250-61. PubMed ID: 12724841
[TBL] [Abstract][Full Text] [Related]
37. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Sharma R; McMillan CR; Tenn CC; Niles LP
Brain Res; 2006 Jan; 1068(1):230-6. PubMed ID: 16375867
[TBL] [Abstract][Full Text] [Related]
38. Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats.
Green-Sadan T; Kuttner Y; Lublin-Tennenbaum T; Kinor N; Boguslavsky Y; Margel S; Yadid G
Exp Neurol; 2005 Jul; 194(1):97-105. PubMed ID: 15899247
[TBL] [Abstract][Full Text] [Related]
39. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor.
Nakao N; Yokote H; Nakai K; Itakura T
J Neurosurg; 2000 Apr; 92(4):659-70. PubMed ID: 10761657
[TBL] [Abstract][Full Text] [Related]
40. Pitx3-transfected astrocytes secrete brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor and protect dopamine neurons in mesencephalon cultures.
Yang D; Peng C; Li X; Fan X; Li L; Ming M; Chen S; Le W
J Neurosci Res; 2008 Nov; 86(15):3393-400. PubMed ID: 18646205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
